Exploring the Diagnostic Potential of Serum Golgi Protein 73 for Hepatic Necroinflammation and Fibrosis in Chronic HCV Infection with Different Stages of Liver Injuries

Qian, Xiangjun; Zheng, Sujun; Wang, Leijie; Yao, Mingjie; Guan, Guoxian; Wen, Xiajie; Xu, Qiang; Chen, Xiangmei; Zhao, Jingmin; Duan, Zhongping; Lu, Fengmin

doi:10.1155/2019/3862024

Cited by 10 publications

(8 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Transient elastography (TE) is the most accurate method with high sensitivity and specificity for advanced fibrosis and is a rapid and noninvasive method widely used in clinical practice 8‐10 . The serum biomarkers chitinase‐3‐like protein 1 (CHI3L1) and Golgi protein 73 (GP73) are good markers of substantial fibrosis and can accurately distinguish among the different stages of liver fibrosis according to the aetiology of viral hepatitis and alcoholic hepatitis 11‐14 . Wang et al showed that CHI3L1 is a useful noninvasive marker for the assessment of liver fibrosis in chronic hepatitis B patients before and during treatment 15 .…”

Section: Introductionmentioning

confidence: 99%

Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication

Kang

Luo

et al. 2021

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Limited data are currently available regarding fibrosis progression after hepatitis C virus (HCV) eradication. The goal of the present study was to evaluate the effects of HCV eradication on liver stiffness measurements (LSMs), aspartate aminotransferase/platelet ratio index (APRI) scores, fibrosis‐4(FIB‐4) scores, chitinase‐3‐like protein 1 (CHI3L1) levels and Golgi protein 73 (GP73) levels in patients with chronic hepatitis C (CHC). One hundred and two patients who received direct antiviral agents (DAAs) therapy at Peking University First Hospital participated in the present study. Clinical information and serum samples were collected at baseline, at the end of treatment (EOT), and at the weeks 12, 24 and 48 after treatment (W12, W24 and W48, respectively). Of the 102 patients, 51 had mild‐to‐moderate fibrosis (F1/F2), and 51 had advanced fibrosis (F3/F4). The LSMs improved for all patients at the EOT, with observed changes of 2.85 kPa, and the decrease continued to W12. However, a more pronounced improvement was noted for the advanced fibrosis (F3/F4) patients, with a change of 3.6 kPa from baseline to the EOT. Significant decreases between the baseline and EOT measurements were observed in the APRI and FIB‐4 scores [0.64 (0.39–1.21) vs. 0.35 (0.26–0.52), p<0.001; 2.53 (1.30–3.91) vs. 1.87 (0.89–2.5), p<0.001], after which the values decreased until W12, with no significant difference observed. Serum CHI3L1 and GP73 levels were profoundly decreased at the EOT compared with those at baseline [134.07 (154.49) vs. 103.75 (98.04), p=0.025; 98.24 (64.76) vs. 88.91 (50.89), p=0.002]. DAA treatments could significantly improve liver fibrosis of CHC patients as evidenced by decreased liver stiffness, APRI scores and FIB‐4 scores. Improvements in liver fibrosis markers (especially serum CHI3L1 and GP73) were prominent in patients with advanced fibrosis, indicating that serum CHI3L1 and GP73 could be noninvasive markers for monitoring fibrosis in CHC patients. Significance Statement The prospective cohort evaluated the effect of direct antiviral agents (DAAs) on fibrosis regression after hepatitis C virus (HCV) eradication of Chinese people in the real‐world study. This study highlighted that rapid and significant fibrosis regression rather than reduction in inflammation was achieved with DAA treatment, and this regression could be detected as early as the end of treatment. We found the serum CHI3L1 and GP73 levels can be used to monitor changes in fibrosis in CHC patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication

Kang

Luo

et al. 2021

Journal of Viral Hepatitis

View full text Add to dashboard Cite

show abstract

“…GP73 is upregulated in many chronic hepatopathies, including chronic viral hepatitis B and C, alcohol-related liver disease, and AIH [ 36 , 37 , 38 , 39 ]. Additionally, GP73 levels were considerably elevated in patients with significant necroinflammation, fibrosis, or cirrhosis [ 36 , 37 , 40 , 41 , 42 ], suggesting that GP73 could be used as a reliable surrogate marker for the detection of advanced fibrosis and cirrhosis but also for the monitoring of patients with liver diseases [ 16 , 37 , 40 , 43 , 44 , 45 ]. Indeed, recent reports have shown that serum GP73 is an accurate biomarker for the detection of significant fibrosis, bearing higher diagnostic accuracy than APRI and FIB-4 scores and that it could be used as a complementary tool to TE [ 20 , 46 ].…”

Section: Discussionmentioning

confidence: 99%

“…This initial concept raised concerns about its specificity in detecting cirrhosis and the early development of HCC. However, subsequent studies by Xiao et al [ 45 ] demonstrated that COMP is slightly expressed in cirrhotic liver and overexpressed in HCC, while recently, Magdaleno et al [ 23 ] showed that COMP contributes to the progression of liver fibrosis by regulating collagen deposition. Interestingly in the latter study, the authors were able to demonstrate how the absence of COMP was associated with decreased hepatic inflammation and fibrosis in two animal models of induced liver fibrosis.…”

Section: Discussionmentioning

confidence: 99%

Serum Cartilage Oligomeric Matrix Protein and Golgi Protein-73: New Diagnostic and Predictive Tools for Liver Fibrosis and Hepatocellular Cancer?

Gatselis

Zachou

Giannoulis

et al. 2021

Cancers

View full text Add to dashboard Cite

The cartilage oligomeric matrix protein (COMP) and Golgi-protein-73 (GP73) have been proposed as markers of liver fibrosis and hepatocellular carcinoma (HCC). Our aim was to assess the performance of the combination of these markers in diagnosing cirrhosis and predicting HCC development. Sera from 288 consecutive patients with chronic liver diseases were investigated by using COMP and GP73-ELISAs. Dual positivity for COMP (>15 U/L) and GP73 (>20 units) was observed in 24 (8.3%) patients, while 30 (10.4%) were GP73(+)/COMP(−), 37/288 (12.8%) GP73(−)/COMP(+), and 197 (68.5%) GP73(−)/COMP(−). Positivity for both markers was associated with cirrhosis [23/24 (95.8%) for GP73(+)/COMP(+) vs. 22/30 (73.3%) for GP73(+)/COMP(−) vs. 25/37 (67.6%) for GP73(−)/COMP(+) vs. 46/197 (23.4%) for GP73(−)/COMP(−); P < 0.001]. The combination of GP73, COMP, the aspartate aminotransferase/platelets ratio index, and the Fibrosis-4 score had even higher diagnostic accuracy to detect the presence of cirrhosis [AUC (95% CI): 0.916 (0.878–0.946)] or significant liver fibrosis (METAVIR ≥ F2) [AUC (95% CI): 0.832 (0.768–0.883)] than each marker alone. Kaplan-Meier analysis showed that positivity for both GP73 and COMP was associated with higher rates of HCC development (P < 0.001) and liver-related deaths (P < 0.001) during follow-up. In conclusion, the combination of GP73 and COMP seems efficient to detect cirrhosis and predict worse outcomes and the development of HCC in patients with chronic liver diseases.

show abstract

“… 25 , 26 However, it has also been reported that serum GP73 is of limited value for the evaluation and monitoring of disease progression, including in the identification of liver necroinflammation and fibrosis in patients with chronic hepatitis C virus infection. 27 Therefore, it is uncertain whether the concentration of GP73 is related to the severity of inflammation in NASH or HF.…”

Section: Introductionmentioning

confidence: 99%

Use of GP73 in the diagnosis of non-alcoholic steatohepatitis and the staging of hepatic fibrosis

Yang

et al. 2021

J Int Med Res

View full text Add to dashboard Cite

Objective To evaluate the utility of Golgi protein 73 (GP73) in the diagnosis of non-alcoholic steatohepatitis (NASH) and hepatic fibrosis (HF) staging. Methods Ninety-one patients with non-alcoholic fatty liver disease (NAFLD) were allocated to NAFL (n = 46) and NASH (n = 45) groups according to their NAFLD activity score (NAS), and there were 30 healthy controls. Serum GP73 was measured by ELISA, GP73 protein expression was evaluated using immunohistochemistry, and FibroScan was used to determine liver hardness. Results The serum GP73 concentrations of the NAFL and NASH groups were significantly higher than those of controls. GP73 expression in the liver of the patients gradually progressed from absent or low to moderate or high. Serum GP73 positively correlated with liver expression, and the serum and liver GP73 of the patients positively correlated with FibroScan value and HF stage. There was a strong positive correlation of the combination of alanine aminotransferase, gamma glutamyl transferase and GP73 with NASH. The combination of serum GP73 and FibroScan value was found to predict NASH (NAS > 4) and advanced HF (stage ≥2) in patients with NAFLD using receiver operating characteristic analysis. Conclusion Serum GP73 may be useful in the diagnosis of NASH and the staging of HF.

show abstract

Exploring the Diagnostic Potential of Serum Golgi Protein 73 for Hepatic Necroinflammation and Fibrosis in Chronic HCV Infection with Different Stages of Liver Injuries

Cited by 10 publications

References 38 publications

Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication

Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication

Serum Cartilage Oligomeric Matrix Protein and Golgi Protein-73: New Diagnostic and Predictive Tools for Liver Fibrosis and Hepatocellular Cancer?

Use of GP73 in the diagnosis of non-alcoholic steatohepatitis and the staging of hepatic fibrosis

Contact Info

Product

Resources

About